Brimonidine Tartrate Ophthalmic Solution 0.15%, Rx Only, Packaged as: a) 5 mL dropper bottle, NDC...

FDA Drug Recall #D-0433-2023 — Class II — March 1, 2023

Recall Summary

Recall Number D-0433-2023
Classification Class II — Moderate risk
Date Initiated March 1, 2023
Status Completed
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Apotex Corp.
Location Weston, FL
Product Type Drugs
Quantity 67,056 bottles

Product Description

Brimonidine Tartrate Ophthalmic Solution 0.15%, Rx Only, Packaged as: a) 5 mL dropper bottle, NDC 60505-0564-1, UPC 3 60505 05641 5; b) 10 mL dropper bottle NDC 60505-0564-2, UPC 3 60505 05642 2; c) 15 mL dropper bottle, NDC 60505-0564-3, UPC 3 60505 05643 9; Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, FL 33326

Reason for Recall

Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility.

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lots: a) TJ9848 Exp. 02/2024, TJ9849 Exp. 02/2024, TK0258 Exp. 04/2024, TK5341 Exp. 04/2024; b) TK0261 Exp. 04/2024; c) TK0262 Exp. 04/2024

Other Recalls from Apotex Corp.

Recall # Classification Product Date
D-0510-2026 Class II Desmopressin Nasal Spray, USP, 10 mcg/0.1 mL, 5... Apr 8, 2026
D-0407-2026 Class II Brimonidine Tartrate/Timolol Maleate Ophthalmic... Mar 5, 2026
D-0676-2025 Class II Brimonidine Tartrate/Timolol Maleate Ophthalmic... Sep 5, 2025
D-0677-2025 Class II Ketorolac Tromethamine Ophthalmic Solution, 0.5... Sep 5, 2025
D-0457-2025 Class II Lacosamide Oral Solution, USP, 10 mg/mL, 200 mL... May 28, 2025

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.